-
Profiling the landscape of carbapenem resistance and hypervirulence in Klebsiella pneumoniae: A global epidemiological analysis of the plasmidome Drug Resist. Updat. (IF 15.8) Pub Date : 2025-05-20
Heng Heng, Ruanyang Sun, Xuemei Yang, Lianwei Ye, Kaichao Chen, Jun Li, Edward Wai-Chi Chan, Rungsheng Li, Rong Zhang, Sheng ChenThe emergence and spread of carbapenem resistance (CR) and hypervirulence (hv) in Klebsiella pneumoniae represent a growing global health threat. Plasmids play an important role in the dissemination of these traits; however, the plasmidome of draft genomes of a large number of K. pneumoniae has not been analyzed so far. To recover K. pneumoniae plasmids, OMAP-KP was developed, achieving a recall rate
-
CSDE1 enhances genotoxic drug resistance in cancer by modulating RPA2 through CSDE1-eIF3a regulatory complex Drug Resist. Updat. (IF 15.8) Pub Date : 2025-05-13
Jia-Jia Cui, Cheng-Xian Guo, Jun Li, Ao-Xiang Guo, Zhao Zhang, Si-Yu Li, Lei-Yun Wang, Xiang-Bin Jia, Hui Guo, Kun Xia, Zheng-Mao Hu, Qian-Ying Ouyang, Yang Wang, Yu-Ting Xie, Zhao-Qian Liu, Jian-Ting Zhang, Wei Wu, Yong-Heng Chen, Ji-Ye YinGenotoxic drug resistance is one of the major obstacles for cancer treatment. Our previous study demonstrates that cold shock domain containing E1 (CSDE1) is associated with drug resistance. In this study, we aim to demonstrate that CSDE1 regulates cellular response to genotoxic drugs and to investigate its mechanism of action in drug resistance.
-
MicroRNA-mediated PTEN downregulation as a novel non-genetic mechanism of acquired resistance to PI3Kα inhibitors of head & neck squamous cell carcinoma Drug Resist. Updat. (IF 15.8) Pub Date : 2025-05-11
Claudio Pulito, Sebastiano Vaccarella, Alina Catalina Palcau, Federica Ganci, Renata Brandi, Carlotta Frascolla, Andrea Sacconi, Valeria Canu, Anna Benedetti, Valentina De Pascale, Sara Donzelli, Anne-Sophie Fisch, Valentina Manciocco, Renato Covello, Fulvia Pimpinelli, Aldo Morrone, Francesco Fazi, Raul Pellini, Paola Muti, Jalna Meens, Christina Karamboulas, Anthony C. Nichols, Sabrina Strano, KonradHead and neck squamous cell carcinomas (HNSCCs) frequently harbor alterations in the PI3K signalling axis and, particularly, in the PIK3CA gene. The promising rationale of using PI3K inhibitors for the treatment of HNSCC has, however, clashed with the spontaneous development of resistance over time.
-
A novel platinum(IV) prodrug, gramine-Pt(IV) enhances chemoimmunotherapy by activating cGAS-STING and modulating TGF-β-MHC-I axis Drug Resist. Updat. (IF 15.8) Pub Date : 2025-05-11
Bowen Ding, Xiaomeng Liu, Zhe Li, Xinru Xie, Jiaqi Li, Jiaqian Wang, Shouyi Li, Pengyu Wang, Yongjie Xie, Xiaoqing Ma, Hongwei Wang, Chengzhi Xie, Xin Qiao, Yumin Wang, Jingyuan Xu, Yukuan Feng, Jihui HaoPlatinum(II) (Pt(II)) drugs, such as cisplatin and oxaliplatin, played critical roles in cancer therapy; however, their efficacy is often limited by significant toxicity and the development of drug resistance. Recently, multi-target platinum(IV) (Pt(IV)) complexes, particularly those optimized with axial ligands, have emerged as promising alternatives enhancing tumor selectivity and drug stability
-
Targeting SLC7A11 with sorafenib sensitizes stereotactic body radiotherapy in colorectal cancer liver metastasis Drug Resist. Updat. (IF 15.8) Pub Date : 2025-05-10
Jiashuai He, Yiran Zhang, Simin Luo, Zhan Zhao, Tianmu Mo, Hanyang Guan, Haoquan Li, Zili Bian, Xiangwei Zhang, Shenghui Qiu, Shijin Liu, Wang Tang, Bo Shi, Minfeng Chen, Dongmei Zhang, Yunlong Pan, Jinghua PanColorectal cancer (CRC) with hepatic metastasis is associated with poor prognosis. Stereotactic body radiotherapy (SBRT) can provide local control for unresectable hepatic metastases of patients with CRC. However, the mechanisms of responsiveness to SBRT in metastatic CRC (mCRC) remain unclear. We aimed to identify a strategy to enhance the efficacy of SBRT in patients with CRC liver metastases and
-
Corrigendum to “Opposite evolution of pathogenicity driven by in vivo wzc and wcaJ mutations in ST11-KL64 carbapenem-resistant Klebsiella pneumoniae” [Drug Resist. Updat. 66 (2023) 100891] Drug Resist. Updat. (IF 15.8) Pub Date : 2025-04-30
Jintao He, Qiucheng Shi, Zhifu Chen, Wang Zhang, Peng Lan, Qingye Xu, Huangdu Hu, Qiong Chen, Jianzhong Fan, Yan Jiang, Belinda Loh, Sebastian Leptihn, Quanming Zou, Jinyong Zhang, Yunsong Yu, Xiaoting Hua -
TEMPORARY REMOVAL: Long non-coding RNA LRTOR drives osimertinib resistance in non-small cell lung cancer by boosting YAP positive feedback loop Drug Resist. Updat. (IF 15.8) Pub Date : 2025-04-23
Zhimin Miao, Zhou Sha, Jianzhong He, Yongkai Liang, Lihua Tan, Yuxin Zhao, Xiaobing Cui, Jinmiao Zhong, Ruting Zhong, Huijun Liang, Wendi Yue, Boyang Qiu, Yunzhen Gao, Lan Zhang, Zixin Teng, Zeen He, Li Chen, Rufei Xiao, Xiaofeng Pei, Chengwei HeThe publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the article will be specified, or the article will be reinstated.
-
Lactylation in cancer progression and drug resistance Drug Resist. Updat. (IF 15.8) Pub Date : 2025-04-21
Yuxiu Sun, He Wang, Zhe Cui, Tingting Yu, Yuanming Song, Haolai Gao, Ruihong Tang, Xinlei Wang, Binru Li, Wenxin Li, Zhe WangLactate plays a crucial role as an energy substrate, metabolite, and signaling molecule in cancer. Lactate has long been considered a byproduct of glycolysis. Still, the lactate shuttle hypothesis has changed the lactate paradigm, revealing the implications of lactate in cellular metabolism and cellular communications that can transcend the compartment barrier and occur within and between different
-
PARP inhibition elicits NK cell-associated immune evasion via potentiating HLA-G expression in tumor Drug Resist. Updat. (IF 15.8) Pub Date : 2025-04-19
Siyuan Wang, Yu Xia, Yiyu Qian, Wen Pan, Pu Huang, Ning Jin, Xin Li, Cheng Xu, Dan Liu, Guangnian Zhao, Yong Fang, Christophe Nicot, Qinglei GaoResistance to poly(ADP-ribose) polymerase inhibitors (PARPi) poses a significant challenge to enhancing the efficacy of cancer treatments. Beyond the cellular mechanisms intrinsic to tumor cells, the modulation of the tumor immune microenvironment is crucial in dictating the responsiveness to pharmacological interventions. Thus, there is a pressing need to elucidate the intricate interplay between
-
MVP-LCN2 axis triggers evasion of ferroptosis to drive hepatocarcinogenesis and sorafenib resistance Drug Resist. Updat. (IF 15.8) Pub Date : 2025-04-17
Jiawen Xu, Bo Wang, Qiaoyu Liu, Sheng Guo, Chen Chen, Jun Wu, Xiaoya Zhao, Mengmeng Li, Zhuang Ma, Shimeng Zhou, Yun Qian, Yijin Huang, Zhangding Wang, Chuanjun Shu, Qingxiang Xu, Jingjing Ben, Qiang Wang, Shouyu WangRNA-binding proteins (RBPs) are critical regulators in tumorigenesis and therapy resistance by modulating RNA metabolism. However, the role of RBPs in hepatocarcinogenesis and progression remains elusive. Here, RBPs screening and integrating analyses identify major vault protein (MVP) as an oncogenic RBP in the occurrence of hepatocellular carcinoma (HCC) and sorafenib resistance via suppressing ferroptosis
-
KpnK48 clone driving hypervirulent carbapenem-resistant Escherichia coli epidemics: Insights into its evolutionary trajectory similar to Klebsiella pneumoniae Drug Resist. Updat. (IF 15.8) Pub Date : 2025-04-08
Meng Wang, Longyang Jin, Ruobing Wang, Qi Wang, Shuyi Wang, Xingyu Wu, Chaoqun Yao, Jukka Corander, Hui WangHypervirulent and carbapenem-resistant pathogens posed a significant and growing threat to global public health. This study focused on the rapid spread of a hypervirulent carbapenem-resistant E. coli (hv-CREC) subclone and its genomic resembles with hypervirulent carbapenem-resistant K. pneumoniae (hv-CRKP), driven by recombination impacting both chromosomal and plasmid gene content.
-
A quiescence-like/TGF-β1-specific CRISPRi screen reveals drug uptake transporters as secondary targets of kinase inhibitors in AML Drug Resist. Updat. (IF 15.8) Pub Date : 2025-03-28
Elahe Rahimian, Masoud Koochak, Sofia Traikov, Michael Schroeder, Silke Brilloff, Silvia Schäfer, Vida Kufrin, Sandra Küchler, Alexander Krüger, Peter Mirtschink, Gustavo Baretton, Evelin Schröck, Denis M. Schewe, Claudia R. Ball, Martin Bornhäuser, Hanno Glimm, Marius Bill, Alexander A. WurmRelapse in acute myeloid leukemia (AML) is driven by resistant subclones that survive chemotherapy. It is assumed that these resilient leukemic cells can modify their proliferative behavior by entering a quiescent-like state, similar to healthy hematopoietic stem cells (HSCs). These dormant cells can evade the effects of cytostatic drugs that primarily target actively dividing cells. Although quiescence
-
Targeting cTRIP12 counteracts ferroptosis resistance and augments sensitivity to immunotherapy in pancreatic cancer Drug Resist. Updat. (IF 15.8) Pub Date : 2025-03-22
Hongyi Lin, Shuncang Zhu, Yinhao Chen, Jinpeng Lu, Chengke Xie, Chengyu Liao, Xiaoxiao Huang, Ge Li, Yongding Wu, Zhiyuan Li, Jianfei Hu, Xinquan Lin, Yifeng Tian, Qiaowei Li, Zuwei Wang, Shi ChenCurrent therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC) have limited efficacy in increasing patient survival rates, largely due to ferroptosis resistance and immunosuppression. The aim of this study is to identify molecular mechanisms associated with ferroptosis resistance and immunosuppression in PDAC tumour cells.
-
Targeting NAT10 attenuates homologous recombination via destabilizing DNA:RNA hybrids and overcomes PARP inhibitor resistance in cancers Drug Resist. Updat. (IF 15.8) Pub Date : 2025-03-22
Zhu Xu, Mingming Zhu, Longpo Geng, Jun Zhang, Jing Xia, Qiang Wang, Hongda An, Anliang Xia, Yuanyuan Yu, Shihan Liu, Junjie Tong, Wei-Guo Zhu, Yiyang Jiang, Beicheng SunRNA metabolism has been extensively studied in DNA double-strand break (DSB) repair. The RNA acetyltransferase N-acetyltransferase 10 (NAT10)-mediated N4-acetylcytidine (ac4C) modification in DSB repair remains largely elusive. In this study, we aim to decipher the role for ac4C modification by NAT10 in DSB repair in hepatocellular carcinoma (HCC).
-
Widespread antibiotic heterotolerance in bacteria remains undetected by resistance assays Drug Resist. Updat. (IF 15.8) Pub Date : 2025-03-15
Bram Van den Bergh, Philip Ruelens, Lieze Agten, Laurence Van Moll, Nele Geerts, Laure Verstraete, Sang Nguyen, Linda De Vooght, Natalie Verstraeten, Paul Cos, Jan MichielsDespite global efforts, antimicrobial resistance persists. Mechanisms like heterotolerance further undermine antibiotic effectiveness. Testing > 1000 clinical strains revealed widespread heterotolerance largely missed by conventional MIC-based diagnostics. Since AMR alone does not predict treatment success, new tests and strategies incorporating tolerance data are urgently needed to significantly improve
-
Role of the sulfur-containing amino acid-ROS axis in cancer chemotherapeutic drug resistance Drug Resist. Updat. (IF 15.8) Pub Date : 2025-03-12
Bingli Wu, Yinwei Cheng, Liyan Li, Zepeng Du, Qianlou Liu, Xinyue Tan, Xin Li, Guozhi Zhao, Enmin LiChemotherapeutic drug resistance remains a major barrier to effective cancer treatment. Drug resistance could be driven in part by adaptive redox remodeling of cancer cells. Paradoxically, drug-resistant malignancies exhibit elevated reactive oxygen species (ROS), as well as amplified antioxidant defenses, which enable cancer cell survival under therapeutic stress. Central to this adaptation is glutathione
-
CD105 blockade restores osimertinib sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer Drug Resist. Updat. (IF 15.8) Pub Date : 2025-03-12
Manish Thiruvalluvan, Sandrine Billet, Zhenqiu Liu, Joseph Lownik, Barliz Waissengrin, Hyoyoung Kim, Anton L. Villamejor, Larry Milshteyn, Xiamo Li, Matthew Gayhart, Manuel Araña, Kamya Sankar, Edwin M. Posadas, Jean Lopategui, Sungyong You, Karen L. Reckamp, Neil A. BhowmickTo investigate the role of CD105 in mediating drug resistance to EGFR-targeted therapy in non-small cell lung cancer (NSCLC).
-
Novel insights into taxane pharmacology: An update on drug resistance mechanisms, immunomodulation and drug delivery strategies Drug Resist. Updat. (IF 15.8) Pub Date : 2025-03-08
Giovanni Luca Beretta, Giuliana Cassinelli, Giacomina Rossi, Amalia Azzariti, Iléana Corbeau, Diego Tosi, Paola PeregoTaxanes are effective in several solid tumors. Paclitaxel, the main clinically available taxane, was approved in the early nineties, for the treatment of ovarian cancer and later on, together with the analogs docetaxel and cabazitaxel, for other malignancies. By interfering with microtubule function and impairing the separation of sister cells at mitosis, taxanes act as antimitotic agents, thereby
-
Overcoming cancer therapy resistance: From drug innovation to therapeutics Drug Resist. Updat. (IF 15.8) Pub Date : 2025-03-08
Jin-Rui Wei, Meng-Yi Lu, Tian-Hua Wei, Joshua S. Fleishman, Hui Yu, Xiao-Li Chen, Xiang-Tu Kong, Shan-Liang Sun, Nian-Guang Li, Ye Yang, Hai-Wen NiOne of the major limitations of cancer therapy is the emergence of drug resistance. This review amis to provide a focused analysis of the multifactorial mechanisms underlying therapy resistance,with an emphasis on actionable insights for developing novel therapeutic strategies. It concisely outlines key factors contributing to therapy resistance, including drug delivery barriers, cancer stem cells
-
TGFβ-activated Asporin interacts with STMN1 to promote prostate cancer docetaxel chemoresistance and metastasis by upregulating the Wnt/β-catenin signaling pathway Drug Resist. Updat. (IF 15.8) Pub Date : 2025-03-08
Shengdong Ge, Jinpeng Cen, Xiaofeng Liu, Yaying Hong, Yuting Tang, Yuzhong Yu, Haolin Li, Tao Xie, Chong Wang, Maoping Cai, Yang Qiu, Xianzi Zeng, Tianming Peng, Qu Li, Qianyi Li, Xingcheng Wu, Xian-Lu Song, Shan-Chao ZhaoProstate cancer (PCa) remains a significant challenge in oncology due to high rates of drug resistance following standard treatment with docetaxel-based chemotherapy. Asporin (ASPN) has been regarded as an oncogene and its upregulation is closely associated with malignant behavior and poor prognosis in multiple cancers. Studies indicated that abnormal activation of the Wnt/β-catenin signaling pathway
-
Aging and senescence: Key players in brain tumor progression and drug resistance Drug Resist. Updat. (IF 15.8) Pub Date : 2025-03-08
Chao Zhang, Neha, Jiaqi Zhang, Prashant Dhaha, Xiaodie Li, Sarad Kumar Mishra, Joshua Fleishman, Suhel Parvez, Saurabh Kumar Jha, Min HuangAging plays a critical role in the development, progression, and therapeutic challenges associated with brain tumors, particularly glioblastomas (GBM). As the population ages, the incidence of brain tumors, including GBM, increases, with aging emerging as a significant prognostic factor influencing survival outcomes. This review examines the molecular mechanisms linking aging and brain tumor progression
-
Methotrexate resistance and its regulatory mechanisms in pediatric tumors and beyond Drug Resist. Updat. (IF 15.8) Pub Date : 2025-03-05
Jing Nie, Lantian Huang, Yan Shen, Hongai Pan, Siwan Wang, Huawei Zhao, Peng Gao, Jufei Yang, Xiaojun Huang, Su Zeng, Jing MiaoMethotrexate (MTX) is a critical antimetabolite drug in treating various pediatric diseases, including acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), brain tumors, osteosarcoma, inflammatory myofibroblastic tumor (IMT), juvenile scleroderma (JS), and juvenile idiopathic arthritis (JIA). MTX acts as a folate antagonist by inhibiting dihydrofolate reductase (DHFR), an enzyme essential
-
Targeting TRAP1-dependent metabolic reprogramming to overcome doxorubicin resistance in quiescent breast cancer Drug Resist. Updat. (IF 15.8) Pub Date : 2025-03-03
Muhammad Zubair Saleem, Ruyi Huang, Yingying Huang, Xin Guo, Yang Liu, Miao Gao, Yinjuan Fan, Zhe-Sheng Chen, Zun-Fu Ke, Shengnan Ye, Jianhua XuTRAP1 is involved in metabolic reprogramming and promotes drug resistance. We aimed to explore whether a novel HSP90 inhibitor, C210, overcomes doxorubicin (DOX) resistance of quiescent breast cancer cells by targeting TRAP1.
-
DTX2 attenuates Lenvatinib-induced ferroptosis by suppressing docosahexaenoic acid biosynthesis through HSD17B4-dependent peroxisomal β-oxidation in hepatocellular carcinoma Drug Resist. Updat. (IF 15.8) Pub Date : 2025-02-28
Zhongyan Zhang, Qi Zhou, Zhenchong Li, Fuxin Huang, Ke Mo, Cheng Shen, Xing Niu, Baohua Hou, Chuanzhao Zhang, Shanzhou HuangEmerging resistance to Lenvatinib, which is used as a first-line agent for the treatment of advanced hepatocellular carcinoma (HCC), is still a concern. The aim of this study was to determine core factors of Lenvatinib resistance (LR) and their underlying molecular mechanisms.
-
The combination of flaxseed lignans and PD-1/ PD-L1 inhibitor inhibits breast cancer growth via modulating gut microbiome and host immunity Drug Resist. Updat. (IF 15.8) Pub Date : 2025-02-28
Hao Wu, Jiena Liu, Xing-Hua Zhang, Shengye Jin, Ping Li, Huidi Liu, Liuying Zhao, Jianyu Wang, Shilu Zhao, Hong-Da Tian, Jin-Ru Lai, Yi Hao, Gui-Rong Liu, Kaijian Hou, Meisi Yan, Shu-Lin Liu, Da PangPatients with breast cancer (BC) who benefit from the PD-1/PD-L1 inhibitor (PDi) is limited, necessitating novel strategies to improve immunotherapy efficacy of BC. Here we aimed to investigate the inhibitory effects of flaxseed lignans (FL) on the biological behaviors of BC and evaluate the roles of FL in enhancing the anticancer effects of PDi.
-
Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs Drug Resist. Updat. (IF 15.8) Pub Date : 2025-02-25
Shuang Dong, Xiaoyu Li, Qing Huang, Yuanxiang Li, Jinjiao Li, Xianmin Zhu, Chang Xue, Runzhi Chen, Yuan Zeng, Jingyi Wu, Yi Zhong, Sheng HuOver the last two decades, advancements in deciphering the intricate interactions between oncology and immunity have fueled a meteoric rise in immunotherapy for non-small cell lung cancer, typified by an explosive growth of immune checkpoint inhibitors. However, resistance to immunotherapy remains inevitable. Herein we unravel the labyrinthine mechanisms of resistance to immunotherapy, characterized
-
Centromere protein U mediates the ubiquitination and degradation of RPS3 to facilitate temozolomide resistance in glioblastoma Drug Resist. Updat. (IF 15.8) Pub Date : 2025-02-21
Jinmin Sun, Wenyu Zhao, Lei Zhang, Sicheng Wu, Senrui Xue, Haowei Cao, Biao Xu, Xinmiao Li, Nan Hu, Tao Jiang, Yixin Xu, Zhifei Wang, Chao Zhang, Jing RenTemozolomide (TMZ) is the first-line chemotherapeutic agent for glioblastoma (GBM) therapy; however, resistance to TMZ remains a major obstacle in GBM treatment. The aim of this study is to elucidate the mechanisms underlying TMZ resistance and explore how to enhance the sensitivity of GBM to TMZ.
-
-
Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis Drug Resist. Updat. (IF 15.8) Pub Date : 2025-02-15
Santiago Ramón-García, Rubén González del Río, María Pilar Arenaz-Callao, Helena I. Boshoff, Joaquín Rullas, Sara Anca, Mónica Cacho Izquierdo, Esther Porras de Francisco, Esther Pérez Herrán, Angel Santos-Villarejo, Alfonso Mendoza-Losana, Santiago Ferrer-Bazaga, Charles J. Thompson, David Barros Aguirre, Robert H. BatesTuberculosis (TB) is historically the world’s deadliest infectious disease. New TB drugs that can avoid pre-existing resistance are desperately needed. The β-lactams are the oldest and most widely used class of antibiotics to treat bacterial infections but, for a variety of reasons, they were largely ignored until recently as a potential treatment option for TB. Recently, a growing body of evidence
-
Sciatic nerve stimulation enhances NK cell cytotoxicity through dopamine signaling and synergizes immunotherapy in triple-negative breast cancer Drug Resist. Updat. (IF 15.8) Pub Date : 2025-02-10
Guangqi Li, Yuting Jiang, Huan Tong, Jifeng Liu, Zedong Jiang, Yunuo Zhao, Keqin Tan, Yu Zhang, Xiaomeng Yin, Hong Yun, Yuxin He, Hu Liao, Jiangjiang Qin, Xuelei MaTriple-negative breast cancer (TNBC) has shown resistance to immunotherapy. Stimulating ProkR2-bearing sensory neurons of the sciatic nerve has been reported to regulate immune function by catecholamine release through the vagal-adrenal axis. We aimed to investigate the impact of sciatic nerve stimulation on anti-tumor immune responses and immunotherapy efficacy in TNBC.
-
Low miR-224–5p in exosomes confers colorectal cancer 5-FU resistance by upregulating S100A4 Drug Resist. Updat. (IF 15.8) Pub Date : 2025-02-06
Yan-yan Yan, Zhuo-fen Deng, Xing-tao Wu, Yu Lu, Zhuang-yan Zhu, Qing Wen, Wei Zhang, Hai-yan Zhang, Xin-zhu Chen, Yu-song Wu, Xue-bing He, Zi-ang Ma, Jin-shuo Li, Hong Bi, Jian-ye ZhangThis study aimed to identify molecular markers that mediate 5-fluorouracil (5-FU) resistance in colorectal cancer (CRC). Exosomes from 5-FU resistant CRC cells (HCT-15/FU) significantly enhanced the resistance to 5-FU and the malignant properties of HCT-15 cells. Double screening of miRNAs in CRC cell-exosomes and serum-exosomes from clinical CRC patients revealed that miR-224–5p was expressed at significantly
-
Harnessing phytochemicals: Innovative strategies to enhance cancer immunotherapy Drug Resist. Updat. (IF 15.8) Pub Date : 2025-02-01
Qianru Zhu, Ruonan Zhang, Ziming Zhao, Tian Xie, Xinbing SuiCancer immunotherapy has revolutionized cancer treatment, but therapeutic ineffectiveness—driven by the tumor microenvironment and immune evasion mechanisms—continues to limit its clinical efficacy. This challenge underscores the need to explore innovative approaches, such as multimodal immunotherapy. Phytochemicals, bioactive compounds derived from plants, have emerged as promising candidates for
-
Rational design of peptides to overcome drug resistance by metabolic regulation Drug Resist. Updat. (IF 15.8) Pub Date : 2025-01-31
Min Sun, Le He, Ran Chen, Mingchen Lv, Zhe-Sheng Chen, Zhen Fan, Yuxiao Zhou, Jinlong Qin, Jianzhong DuChemotherapy is widely used clinically, however, its efficacy is often compromised by the development of drug resistance, which arises from prolonged administration of drugs or other stimuli. One of the driven causes of drug resistance in tumors or bacterial infections is metabolic reprogramming, which alters mitochondrial metabolism, disrupts metabolic pathways and causes ion imbalance. Bioactive
-
The uptake of extracellular vesicles: Research progress in cancer drug resistance and beyond Drug Resist. Updat. (IF 15.8) Pub Date : 2025-01-31
Luomeng Qian, Pangzhou Chen, Shiwu Zhang, Zhenglu Wang, Yuan Guo, Vasili Koutouratsas, Joshua S. Fleishman, Chuanqiang Huang, Sihe ZhangExtracellular vesicles (EVs) are heterogeneous vesicles released by donor cells that can be taken up by recipient cells, thus inducing cellular phenotype changes. Since their discovery decades ago, roles of EVs in modulating initiation, growth, survival and metastasis of cancer have been revealed. Recent studies from multifaceted perspectives have further detailed the contribution of EVs to cancer
-
Structural and functional analyses of STM14_5441-STM14_5442: A potential mechanism for persister formation against aminoglycosides Drug Resist. Updat. (IF 15.8) Pub Date : 2025-01-29
Hyun-Jong Eun, Seok-Won Jang, Ju-Hyun Park, Jooyeon Lee, Ki-Young Lee, Eun-Jin Lee, Bong-Jin LeeThe ability to eliminate bacterial persister cells is still a medical challenge that has yet to be overcome. These cells represent a unique subpopulation within bacterial communities and are characterized by a reduced susceptibility to antibiotics with growth retardation. In this study, we investigated the molecular basis of persister formation in Salmonella Typhimurium 14028 s under aminoglycoside
-
B7-H3-liquid biopsy for the characterization and monitoring of the dynamic biology of prostate cancer Drug Resist. Updat. (IF 15.8) Pub Date : 2025-01-28
Yong Ju, Joshua Watson, Jasmine J. Wang, Ying-Tzu Yen, Lilit Gevorkian, Zijing Chen, Kai Han Tu, Brenda Salumbides, Aaron Phung, Chen Zhao, Hyoyong Kim, You-Ren Ji, Ryan Y. Zhang, Junseok Lee, Jun Gong, Kevin Scher, Sungyong You, Jie-Fu Chen, Hsian-Rong Tseng, Yazhen Zhu, Edwin M. PosadasB7-H3 is a promising target for cancer therapy, notably in prostate cancer (PCa), particularly in metastatic, castration-resistant PCa (mCRPC). With the development of B7-H3-targeted therapies, there is a need for a rapid, reliable, and cost-effective method to detect and monitor B7-H3 expression. Leveraging their abundance and stability, we developed a liquid biopsy assay using extracellular vesicles
-
Dynamic evolution of KPC-230-mediated resistance to ceftazidime-avibactam during the treatment of carbapenem-resistant Klebsiella pnenmoniae Drug Resist. Updat. (IF 15.8) Pub Date : 2025-01-25
Xi Li, Longjie Zhou, Huaqiong HuangThe molecular mechanisms driving the development of KPC-230-mediated resistance to ceftazidime-avibactam during treatment of carbapenem-resistant Klebsiella pneumoniae infection was elucidated by analyzing specimens collected from a patient, including one blaKPC-230-positive and three blaKPC-2-positive Klebsiella pnenmoniae isolates.
-
Global dissemination of Klebsiella pneumoniae in surface waters: Genomic insights into drug resistance, virulence, and clinical relevance Drug Resist. Updat. (IF 15.8) Pub Date : 2025-01-21
Damian Rolbiecki, Edyta Kiedrzyńska, Małgorzata Czatzkowska, Marcin Kiedrzyński, Ewa Korzeniewska, Monika HarniszThe aquatic environment is a major pathway for the spread of antibiotic resistance (AR) among microorganisms. Among these, Klebsiella pneumoniae reveals high genome plasticity, adaptability, and the ability to colonize humans, animals, and the natural environment, awarding it a significant role in the spread of AR. This work presents an in-depth analysis of the whole sequences of 149 K. pneumoniae
-
Osmotic stress influences microtubule drug response via WNK1 kinase signaling Drug Resist. Updat. (IF 15.8) Pub Date : 2025-01-18
Ana Monfort-Vengut, Natalia Sanz-Gómez, Sandra Ballesteros-Sánchez, Beatriz Ortigosa, Aitana Cambón, Maria Ramos, Ángela Montes-San Lorenzo, María Escribano-Cebrián, Juan Manuel Rosa-Rosa, Joaquín Martínez-López, Ricardo Sánchez-Prieto, Rocío Sotillo, Guillermo de CárcerIon homeostasis is critical for numerous cellular processes, and disturbances in ionic balance underlie diverse pathological conditions, including cancer progression. Targeting ion homeostasis is even considered as a strategy to treat cancer. However, very little is known about how ion homeostasis may influence anticancer drug response. In a genome-wide CRISPR-Cas9 resistance drug screen, we identified
-
Peptide-based PET/CT imaging visualizes PD-L1-driven radioresistance in glioblastoma Drug Resist. Updat. (IF 15.8) Pub Date : 2025-01-09
Yong Wang, Zhiguo Liu, Yang Li, Kelin Wang, Chunhui Yuan, Jian Shi, Jiazhong Ren, Shijie Wang, Jinping Wang, Miaoqing Zhao, Man HuRadioresistance remains a great challenge for radiotherapy in the treatment of glioblastoma (GBM). PD-L1 expression is a key contributor to radioresistance and immune escape in GBM. The lack of effective methods to monitor the change of PD-L1 during radiotherapy in patients limits timely intervention and management of the resistance. Here, we developed a novel peptide tracer [18F]AlF-NOTA-PCP2 for
-
Organoid models of drug resistant gastric adenosquamous carcinoma: Recapitulating tumor features and refining precision treatment Drug Resist. Updat. (IF 15.8) Pub Date : 2025-01-07
Kuan Li, Wenchao Li, Shuying Fu, Chen Wang, Kexin Wang, Huan Yang, Yumei Xian, Tengfei Hao, Shiwei Zhang, Tianshun Gao, Jie Zhou, Jia Li, Changhua Zhang, Wei Chen, Leli Zeng, Yulong HeOrganoids were successfully established from primary tumor and its metastatic lymph nodes of a patient. These organoids faithfully replicated tumor pathology and genetic characteristics. Organoid-based drug screening was conducted, which revealed significant difference in sensitivity to drugs between organoids dervived from primary tumor versus metastatic lymph nodes. The results guided clinical decisions
-
Exploring treatment-driven subclonal evolution of prognostic triple biomarkers: Dual gene fusions and chimeric RNA variants in novel subtypes of acute myeloid leukemia patients with KMT2A rearrangement Drug Resist. Updat. (IF 15.8) Pub Date : 2025-01-02
Yi Xu, Shengwen Calvin Li, Jeffrey Xiao, Qian Liu, Durga Cherukuri, Yan Liu, Saied Mirshahidi, Jane Xu, Xuelian Chen, Dadrastoussi Homa, Julian Olea, Kaijin Wu, Kevin R. Kelly, Fengzhu Sun, Ruihao Huang, Xiaoqi Wang, Qin Wen, Xi Zhang, Cristina M. Ghiuzeli, Esther Chong, Hisham Abdel-Azim, Mark E. Reeves, David J. Baylink, Huynh Cao, Jiang F. ZhongChromosomal rearrangements (CR) initiate leukemogenesis in approximately 50 % of acute myeloid leukemia (AML) patients; however, limited targeted therapies exist due to a lack of accurate molecular and genetic biomarkers of refractory mechanisms during treatment. Here, we investigated the pathological landscape of treatment resistance and relapse in 16 CR-AML patients by monitoring cytogenetic, RNAseq
-
YTHDF2-mediated m6A modification of ONECUT2 promotes stemness and oxaliplatin resistance in gastric cancer through transcriptionally activating TFPI Drug Resist. Updat. (IF 15.8) Pub Date : 2025-01-02
Xingdi Fan, Fangyi Han, Haocheng Wang, Zhilin Shu, Bowen Qiu, Fanan Zeng, Hongzhen Chen, Ziying Wu, Yongwei Lin, Zhien Lan, Zhiwei Ye, Yao Ying, Tiansu Geng, Ziqian Xian, Xing Niu, Junming Wu, Ke Mo, Kehong Zheng, Yaping Ye, Chunhui CuiChemoresistance results in poor outcomes of patients with gastric cancer (GC). This study aims to identify oxaliplatin resistance-related cell subpopulations in the tumor microenvironment (TME) and decipher the involved molecular mechanisms.
-
N6-methyladenosine modification of 3'tRF-AlaAGC impairs PD-1 blockade efficacy by promoting lactic acid accumulation in the tumor microenvironment of gastric carcinoma Drug Resist. Updat. (IF 15.8) Pub Date : 2024-12-26
Weiguo Xu, Bin Zhou, Ping Wang, Yuyan Ma, Yu Jiang, Dongping Mo, Jun Wu, Jingjing Ma, Xiao Wang, Yinxing Miao, Yong Nian, Junyu Zheng, Jie Li, Feng Yan, Gang LiThe balance between CD8+ T cells and regulatory T (Treg) cells in the tumor microenvironment (TME) plays a crucial role in the immune checkpoint inhibition (ICI) therapy in gastric carcinoma (GC). However, related factors leading to the disturbance of TME and resistance to ICI therapy remain unknown. In this study, we applied N6-methyladenosine (m6A) small RNA Epitranscriptomic Microarray and screened
-
Molecular subtype changes after acquiring resistance to tarlatamab in small cell lung cancer Drug Resist. Updat. (IF 15.8) Pub Date : 2024-12-26
Hyung-Min Ahn, Seog-Yun Park, Yura Choi, Jaemin Kim, Youngjoo LeeTarlatamab, a novel bispecific T-cell engager, has demonstrated unprecedented efficacy in patients with small cell lung cancer. However, there is no known mechanism of resistance to tarlatamab. This study suggests that a transcriptional expression shift might be associated with acquired resistance to tarlatamab.
-
Research progress on gene mutations and drug resistance in leukemia Drug Resist. Updat. (IF 15.8) Pub Date : 2024-12-26
Xiangyu Ma, Jiamin Xu, Yanan Wang, Joshua S. Fleishman, Hao Bing, Boran Yu, Yanming Li, Letao Bo, Shaolong Zhang, Zhe-Sheng Chen, Libo ZhaoLeukemia is a type of blood cancer characterized by the uncontrolled growth of abnormal cells in the bone marrow, which replace normal blood cells and disrupt normal blood cell function. Timely and personalized interventions are crucial for disease management and improving survival rates. However, many patients experience relapse following conventional chemotherapy, and increasing treatment intensity
-
Silent circulation of plasmid-borne tet(X6) and blaOXA-58 genes in a community-acquired Acinetobacter baumannii strain Drug Resist. Updat. (IF 15.8) Pub Date : 2024-12-25
Huiqiong Jia, Qingchao Tong, Le Wang, Yuye Wu, Xinyang Li, Shuangshuang Li, Yingying Kong, Yingying Zhang, João Pedro Rueda Furlan, Nwai Oo Khine, Patrick Butaye, Jun Zhang, Qing Yang, Zhi RuanTo characterize the genomic features of a community-acquired Acinetobacter baumannii strain, co-carrying tet(X6) and blaOXA-58 genes, but was susceptible to tigecycline and carbapenems. The tet(X6) and blaOXA-58 genes were found on a 149,518 bp non-conjugative plasmid. The blaOXA-58 gene was silent, due to the presence of an intact ISAba3-like element upstream, which rendered the strain susceptible
-
Wip1 phosphatase activator QGC-8–52 specifically sensitizes p53-negative cancer cells to chemotherapy while protecting normal cells Drug Resist. Updat. (IF 15.8) Pub Date : 2024-12-24
Ke Wu, Xiao-xiao Ge, Xiao-fan Duan, Jie-qing Li, Kun Wang, Qiao-Hong Chen, Zhi-min Huang, Wei-yan Zhang, Yong Wu, Qun LiPP2C serine-threonine phosphatase Wip1 plays an important role in normal tissue homeostasis, stress signaling and pathogenesis of various human diseases. It is an attractive drug target for cancer treatment and inhibition of its expression or activity constitute a novel therapeutic intervention strategy to prevent the development of various cancers. However, previous strategies for Wip1 suppression
-
WITHDRAWN: Low miR-224-5p in exosomes confers colorectal cancer 5-FU resistance by upregulating S100A4 Drug Resist. Updat. (IF 15.8) Pub Date : 2024-12-16
Yan-yan Yan, Zhuo-fen Deng, Xing-tao Wu, Yu Lu, Zhuang-yan Zhu, Qing Wen, Wei Zhang, Hai-yan Zhang, Xin-zhu Chen, Yu-song Wu, Xue-bing He, Zi-ang Ma, Jin-shuo Li, Hong Bi, Jian-ye Zhang -
Association of idealized amphiphiles and protease inhibitors: Conferring antimicrobial peptides with stable antibacterial activity under physiological conditions to combat multidrug-resistant bacteria Drug Resist. Updat. (IF 15.8) Pub Date : 2024-12-09
Yongjie Zhu, Bowen Li, Wanying Xu, Yuanmengxue Wang, Guoyu Li, Chongpeng Bi, Anshan Shan, Changxuan ShaoThe unstable antimicrobial activity of antimicrobial peptides (AMPs) under physiological conditions (especially the degradation instigated proteases) seems to be a persistent impediment for their successful implementation in clinical trials. Consequently, our objective was to devise AMP engineering frameworks that could sustain robust antibacterial efficacy within physiological environments.
-
Fasting-mimicking diet potentiates anti-tumor effects of CDK4/6 inhibitors against breast cancer by suppressing NRAS- and IGF1-mediated mTORC1 signaling Drug Resist. Updat. (IF 15.8) Pub Date : 2024-12-06
Sebastian Brandhorst, Valter D. LongoFasting-mimicking diet (FMD) cycles, defined as 3–5 day periods of a calorie-restricted, low-protein, low-carbohydrate, and high-fat diet, have emerged as a dietary approach to delay cancer initiation and progression in both autograft and xenograft mouse models and as a safe and feasible approach to decrease risk factors for cancer and other age-related pathologies in humans. A substantial number of
-
Global phylogeography and antibiotic resistance characteristics of Morganella: An epidemiological, spatial, comparative genomic study Drug Resist. Updat. (IF 15.8) Pub Date : 2024-12-05
Qian Liu, Hong Shen, Ming Wei, Xi Chen, Li Gu, Wentao ZhuMorganella morganii has been recognized as an important opportunistic pathogen that is becoming increasingly prevalent worldwide. However, the current global evolutionary dynamics and emergence of ARGs remain obscure. The present study determined the global distribution, genomic classification, phylogeny, and monitor longitudinal resistome changes. During 1900–2024, a total of 1027 non-duplicate Morganella
-
5-methylcytosine methylation of MALAT1 promotes resistance to sorafenib in hepatocellular carcinoma through ELAVL1/SLC7A11-mediated ferroptosis Drug Resist. Updat. (IF 15.8) Pub Date : 2024-12-04
Chuan-Jian Shi, Feng-Xiang Pang, Yu-He Lei, Li-Qiang Deng, Fu-Zhen Pan, Zhi-Qing Liang, Tian Xie, Xian-Lin Wu, Yu-Yan Wang, Yan-Fang Xian, Wei-Qiang Zeng, Han-Li Lin, Jin-Fang ZhangEmerging evidence demonstrates that long non-coding RNAs (lncRNAs) play a crucial role in sorafenib resistance in hepatocellular carcinoma (HCC), and lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a dysregulated lncRNA in sorafenib-resistant HCC cells. However, the underlying regulatory mechanisms of MALAT1 in sorafenib-resistant HCC cells remain unclear. In the present study
-
CEA-induced PI3K/AKT pathway activation through the binding of CEA to KRT1 contributes to oxaliplatin resistance in gastric cancer Drug Resist. Updat. (IF 15.8) Pub Date : 2024-12-03
Yifan Chen, Yulong Mi, Song Tan, Yizhen Chen, Shaolin Liu, Shengtao Lin, Changshun Yang, Weifeng Hong, Weihua LiThe serum level of carcinoembryonic antigen (CEA) has prognostic value in patients with gastric cancer (GC) receiving oxaliplatin-based chemotherapy. As the molecular functions of CEA are increasingly uncovered, its role in regulating oxaliplatin resistance in GC attracts attention.
-
Reshaping the battlefield: A decade of clonal wars among Staphylococcus aureus in China Drug Resist. Updat. (IF 15.8) Pub Date : 2024-11-29
Wangxiao Zhou, Ye Jin, Pan Chen, Qi Ge, Xu Dong, Yunbo Chen, Minghua Jiang, Yonghong XiaoLong-term comprehensive studies on the genomic epidemiology of both methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) isolates are limited in China. Here, we aimed to assess the genomic epidemiological characteristics and population dynamics of S. aureus in China.
-
Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies Drug Resist. Updat. (IF 15.8) Pub Date : 2024-11-28
Defa Wu, Qian Sun, Haolin Tang, Huan Xiao, Jiaxiang Luo, Liang Ouyang, Qiu SunOver the past two decades, tyrosine kinase inhibitors (TKIs) have rapidly emerged as pivotal targeted agents, offering promising therapeutic prospects for patients. However, as the cornerstone of targeted therapies, an increasing number of TKIs have been found to develop acquired resistance during treatment, making the challenge of overcoming this resistance a primary focus of current research. This
-
Why and how citrate may sensitize malignant tumors to immunotherapy Drug Resist. Updat. (IF 15.8) Pub Date : 2024-11-26
Philippe Icard, Mathilde Prieto, Antoine Coquerel, Ludovic Fournel, Joseph Gligorov, Johanna Noel, Adrien Mouren, Anthony Dohan, Marco Alifano, Luca SimulaImmunotherapy, either alone or in combination with chemotherapy, has demonstrated limited efficacy in a variety of solid cancers. Several factors contribute to explaining primary or secondary resistance. Among them, cancer cells, whose metabolism frequently relies on aerobic glycolysis, promote exhaustion of cytotoxic immune cells by diverting the glucose in the tumor microenvironment (TME) to their
-
Blockade of purine metabolism reverses macrophage immunosuppression and enhances anti-tumor immunity in non-small cell lung cancer Drug Resist. Updat. (IF 15.8) Pub Date : 2024-11-23
Li Yang, Aitian Li, Weina Yu, Huishang Wang, Lei Zhang, Dan Wang, Ying Wang, Ru Zhang, Qingyang Lei, Zhangnan Liu, Shanshan Zhen, Haiming Qin, Yaqing Liu, Yang Yang, Xian-Lu Song, Yi ZhangImmune checkpoint blockade therapy is not effective in most patients with non-small cell lung cancer (NSCLC) due to the immunosuppressive tumor microenvironment. Macrophages are key components of tumor-infiltrating immune cells and play a critical role in immunosuppression, which can be mediated by cell-intrinsic metabolism. This study aimed to evaluate whether macrophages regulate NSCLC progression
-
Post-translational modifications in drug resistance Drug Resist. Updat. (IF 15.8) Pub Date : 2024-11-21
Chenggui Miao, Yurong Huang, Cheng Zhang, Xiao Wang, Bing Wang, Xinyue Zhou, Yingqiu Song, Peng Wu, Zhe-Sheng Chen, Yibin FengResistance to antitumor drugs, antimicrobial drugs, and antiviral drugs severely limits treatment effectiveness and cure rate of diseases. Protein post-translational modifications (PTMs) represented by glycosylation, ubiquitination, SUMOylation, acetylation, phosphorylation, palmitoylation, and lactylation are closely related to drug resistance. PTMs are typically achieved by adding sugar chains (glycosylation)
-
AI-driven visualization tool for analyzing data and predicting drug-resistant outbreaks Drug Resist. Updat. (IF 15.8) Pub Date : 2024-11-19
Yoshiyasu TakefujiA tool was developed to identify potential disease outbreaks using pathogen and serotype data. By analyzing isolate numbers and comparing them to a two-year average, the tool highlights anomalies suggestive of outbreaks. When applied to Salmonella data, it revealed potential outbreaks related to specific serotypes.